{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06216886",
            "orgStudyIdInfo": {
                "id": "66036"
            },
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "OnabotulinumtoxinA for Trigeminal Neuralgia",
            "officialTitle": "Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.",
            "therapeuticArea": [
                "Other"
            ],
            "study": "onabotulinumtoxina-for-trigeminal-neuralgia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-11",
            "studyFirstSubmitQcDate": "2024-01-11",
            "studyFirstPostDateStruct": {
                "date": "2024-01-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Meredith Barad",
                "investigatorTitle": "Clinical Associate Professor of Anesthesiology (Pain) and Neurology & Neurological Sciences",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.",
            "detailedDescription": "This study will offer onabotulinumtoxin A (Botox) delivered intradermally into the region of pain for the patient with trigeminal neuralgia. Should they derive benefit from the procedure (as determined by decrease in the frequency of attacks), then they will be randomized to receive either onabotulinumtoxin A or saline and followed for 3 months. This study hopes to provide strong data that this is a treatment option for patients with TN who have failed medications, but are not ready for or do not want to undergo surgery."
        },
        "conditionsModule": {
            "conditions": [
                "Trigeminal Neuralgia"
            ],
            "keywords": [
                "botox",
                "injection",
                "trigeminal neuralgia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "This will be a randomized controlled trial of onabotulinumtoxinA versus Saline intradermal injections into the affected trigeminal distributions. The RCT will be enriched with all participants being initial responders to a preliminary round of onatbotulinumtoxinA.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "After the initial round of botox, all participants will be randomized to either onabotA or saline. The randomization will performed by a provider who is not a care provider or proceduralist.\n\nThe patient will be blinded, the proceduralist will be blinded and the care provider will be blinded. Data will be stored and not reviewed by research team until the study closes.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "OnabotulinumtoxinA",
                    "type": "EXPERIMENTAL",
                    "description": "Intradermal injections will be placed in the affected trigeminal territories according to a specific facial map that we have developed.",
                    "interventionNames": [
                        "Drug: OnabotulinumtoxinA 100 UNT [Botox]"
                    ]
                },
                {
                    "label": "Saline",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "The same procedure will be followed as above, but saline will be injected instead of onabotA",
                    "interventionNames": [
                        "Drug: Sodium Chloride 0.9% for Injection, Preservative Free"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "OnabotulinumtoxinA 100 UNT [Botox]",
                    "description": "Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.",
                    "armGroupLabels": [
                        "OnabotulinumtoxinA"
                    ],
                    "otherNames": [
                        "Botox"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Sodium Chloride 0.9% for Injection, Preservative Free",
                    "description": "intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.",
                    "armGroupLabels": [
                        "Saline"
                    ],
                    "otherNames": [
                        "Saline"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Number of TN Attacks per week",
                    "description": "Frequency of TN attacks before and after onabotA injection over a seven day period",
                    "timeFrame": "compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment))"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in PROMIS Computer Adaptive Tests (PROMIS PROFILE CAT V1.0 -29)",
                    "description": "Computer adaptive tests (CATs) assess anxiety, depression, fatigue, pain interference, physical function, sleep disturbance and ability to participate in social roles and activities, and pain intensity.",
                    "timeFrame": "compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)"
                },
                {
                    "measure": "Change in Severity of Attacks Based using the numerical rating scale (NRS)",
                    "description": "Average severity of attack over a 7 day period",
                    "timeFrame": "compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)"
                },
                {
                    "measure": "Change In Baseline Pain Average using the numerical rating scale (NRS)",
                    "description": "baseline pain average over a seven day period",
                    "timeFrame": "compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)"
                },
                {
                    "measure": "Change In Acute Medication Use",
                    "description": "Number of doses of any acute medication use over a 7 day period",
                    "timeFrame": "compare data from week -1(7 days prior to starting study) and week 4(7 days during the 4th week after treatment)"
                },
                {
                    "measure": "Change In Patient Global Impression of Change",
                    "description": "A single self administered question given at week 4",
                    "timeFrame": "week 4"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nMen and women age 18 or older\n\n* Judged to be of legal competence\n* Sufficient knowledge of written and spoken English\n* Capable of attending regular in-person visits\n* Have failed/not a candidate/do not want surgery\n* Inadequate response to medication - at least 2 trials\n* Meeting ICHD criteria for Classical Trigeminal Neuralgia 13.1.1.1\n* Patients with frequency \\> 10 attacks per week\n* Stable dose of medications in the last 2 weeks\n\nExclusion Criteria:\n\n* Secondary or Idiopathic TN, or Painful Trigeminal Neuropathy as defined by the ICHD (13.1.1.2, 13.1.1.3, 13.1.2)\n* Pregnant or breast feeding (while it is rare that a patient will be pregnant with TN, there is not sufficient data to say definitively that onabotA is ok to use during pregnancy and nursing, it is still rated Class C)\n* Neuromuscular disease\n* On aminoglyocosides\n* Not currently enrolled in any other studies",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Meredith Barad, MD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Meredith Barad",
                    "status": "RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Meredith Study Team",
                            "role": "CONTACT",
                            "phone": "650-721-7218",
                            "email": "mbarad@stanford.edu"
                        },
                        {
                            "name": "Meredith Barad, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "type": "BACKGROUND",
                    "citation": "undefined"
                },
                {
                    "pmid": "27377706",
                    "type": "BACKGROUND",
                    "citation": "Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TL, Mostafa MR, Huy NT, Hirayama K. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016 Dec;17(1):63. doi: 10.1186/s10194-016-0651-8. Epub 2016 Jul 5."
                },
                {
                    "pmid": "31541518",
                    "type": "BACKGROUND",
                    "citation": "Wei J, Zhu X, Yang G, Shen J, Xie P, Zuo X, Xia L, Han Q, Zhao Y. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. Brain Behav. 2019 Oct;9(10):e01409. doi: 10.1002/brb3.1409. Epub 2019 Sep 21."
                },
                {
                    "pmid": "23964790",
                    "type": "BACKGROUND",
                    "citation": "Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, Jin L. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain. 2013 Aug 21;14(1):72. doi: 10.1186/1129-2377-14-72."
                },
                {
                    "pmid": "24952600",
                    "type": "BACKGROUND",
                    "citation": "Li S, Lian YJ, Chen Y, Zhang HF, Ma YQ, He CH, Wu CJ, Xie NC, Zheng YK, Zhang Y. Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain. 2014 Jun 22;15(1):43. doi: 10.1186/1129-2377-15-43."
                },
                {
                    "pmid": "24045604",
                    "type": "BACKGROUND",
                    "citation": "Zuniga C, Piedimonte F, Diaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013 Sep-Oct;36(5):146-50. doi: 10.1097/WNF.0b013e31829cb60e."
                },
                {
                    "pmid": "25263254",
                    "type": "BACKGROUND",
                    "citation": "Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N, Wu C. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014 Sep 27;15(1):65. doi: 10.1186/1129-2377-15-65."
                },
                {
                    "pmid": "24251833",
                    "type": "BACKGROUND",
                    "citation": "Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013 Nov 19;14(1):92. doi: 10.1186/1129-2377-14-92."
                },
                {
                    "pmid": "35944492",
                    "type": "BACKGROUND",
                    "citation": "Tangney T, Heydari ES, Sheldon BL, Shetty A, Argoff CE, Khazen O, Pilitsis JG. Botulinum Toxin as an Effective Treatment for Trigeminal Neuralgia in Surgical Practices. Stereotact Funct Neurosurg. 2022;100(5-6):314-320. doi: 10.1159/000526053. Epub 2022 Aug 9."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "NIH PROMIS MEASURES",
                    "url": "https://www.healthmeasures.net/explore-measurement-systems/promis"
                },
                {
                    "label": "Quality of Life Scale instructions and References",
                    "url": "https://resourcelibrary.stfm.org/viewdocument/quality-of-life-scale-qols?CommunityKey=2751b51d-483f-45e2-81de-4faced0a290a&amp;tab=librarydocuments"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014277",
                    "term": "Trigeminal Neuralgia"
                },
                {
                    "id": "D000009437",
                    "term": "Neuralgia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010523",
                    "term": "Peripheral Nervous System Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000010146",
                    "term": "Pain"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000020433",
                    "term": "Trigeminal Nerve Diseases"
                },
                {
                    "id": "D000005156",
                    "term": "Facial Neuralgia"
                },
                {
                    "id": "D000005155",
                    "term": "Facial Nerve Diseases"
                },
                {
                    "id": "D000009059",
                    "term": "Mouth Diseases"
                },
                {
                    "id": "D000009057",
                    "term": "Stomatognathic Diseases"
                },
                {
                    "id": "D000003389",
                    "term": "Cranial Nerve Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12381",
                    "name": "Neuralgia",
                    "asFound": "Neuralgia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17029",
                    "name": "Trigeminal Neuralgia",
                    "asFound": "Trigeminal Neuralgia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13432",
                    "name": "Peripheral Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M22229",
                    "name": "Trigeminal Nerve Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21089",
                    "name": "Facies",
                    "relevance": "LOW"
                },
                {
                    "id": "M8299",
                    "name": "Facial Neuralgia",
                    "relevance": "LOW"
                },
                {
                    "id": "M8298",
                    "name": "Facial Nerve Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12019",
                    "name": "Mouth Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12017",
                    "name": "Stomatognathic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6605",
                    "name": "Cranial Nerve Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5717",
                    "name": "Trigeminal Neuralgia",
                    "asFound": "Trigeminal Neuralgia",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC07",
                    "name": "Mouth and Tooth Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019274",
                    "term": "Botulinum Toxins, Type A"
                },
                {
                    "id": "C000542869",
                    "term": "abobotulinumtoxinA"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009465",
                    "term": "Neuromuscular Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000065087",
                    "term": "Acetylcholine Release Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21257",
                    "name": "Botulinum Toxins, Type A",
                    "asFound": "Overnight",
                    "relevance": "HIGH"
                },
                {
                    "id": "M250193",
                    "name": "abobotulinumtoxinA",
                    "asFound": "Overnight",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5183",
                    "name": "Botulinum Toxins",
                    "relevance": "LOW"
                },
                {
                    "id": "M3473",
                    "name": "Acetylcholine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                }
            ]
        }
    },
    "hasResults": false
}